IRVINE, Calif., Sept. 8 /PRNewswire/ — Cardiogenesis
Corporation (OTCQB: CGCP) today announced that the Wall Street
Reporter has interviewed Cardiogenesis’ Executive Chairman Paul J.
McCormick. The interview includes a discussion of the
Company’s results for the first half of 2010, including an
approximate 17% year-over-year increase in disposable handpiece
sales for the first half of 2010 and an overview of the company and
its core technologies. The interview also covers
Cardiogenesis’ progress towards initiating a pivotal trial for its
PHOENIX™ System in patients with refractory angina. The
PHOENIX handpiece is the first device specifically designed to
allow physician-directed tissue stimulation and injections of
biologic or pharmacologic agents to pre-determined areas of
myocardium.
The interview is available at www.wallstreetreporter.com,
or directly via this link:
http://www.wallstreetreporter.com/2010/09/cardiogenesis-corporation-otc-qb-cgcp-management-interview/.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the
therapies for the treatment of chronic cardiac ischemia. The
company’s market leading Holmium:YAG laser system and disposable
fiber-optic accessories are used to perform a FDA-cleared surgical
procedure known as Transmyocardial Revascularization (TMR) to treat
patients suffering from angina. Surgical products and accessories
for the Cardiogenesis TMR procedure, which are marketed in the U.S.
and around the world, have been shown to reduce angina and improve
the quality of life in patients with coronary artery disease.
For more information on the company and its products, please
visit the Cardiogenesis website at http://www.cardiogenesis.com.<
‘/>”/>
SOURCE
